Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $9.50.

A number of research firms recently commented on XERS. Barclays initiated coverage on Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th.

Insiders Place Their Bets

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the transaction, the director directly owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Johnson sold 135,400 shares of Xeris Biopharma stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director owned 698,083 shares in the company, valued at approximately $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 206,976 shares of company stock valued at $1,497,495. 6.47% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of the stock. Nuveen LLC acquired a new position in Xeris Biopharma in the first quarter worth approximately $12,240,000. UBS Group AG raised its holdings in Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after buying an additional 1,554,869 shares during the period. Qube Research & Technologies Ltd lifted its stake in Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after buying an additional 1,245,188 shares in the last quarter. Parkman Healthcare Partners LLC lifted its stake in Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after buying an additional 1,201,943 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Trading Up 4.7%

Shares of NASDAQ XERS opened at $7.34 on Friday. The stock has a fifty day moving average price of $7.88 and a 200 day moving average price of $6.86. Xeris Biopharma has a 12-month low of $3.14 and a 12-month high of $10.08. The company has a market cap of $1.22 billion, a P/E ratio of -73.39 and a beta of 0.57.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. On average, sell-side analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.